Zymeworks (ZYME) closed at $26.24 on November 13, 2026, down 0.9% from the previous close, on volume of 733,034 shares (30-day average 1,338,279).
Data as of November 13, 2026.
13-Nov-2026
Zymeworks (ZYME) Gets a Buy from J.P. Morgan
TipRanks (Fri, 13-Nov 7:16 AM ET)
Citi Sticks to Its Buy Rating for Zymeworks (ZYME)
TipRanks (Wed, 11-Nov 5:37 AM ET)
TD Cowen Sticks to Its Buy Rating for Zymeworks (ZYME)
TipRanks (Tue, 10-Nov 7:55 AM ET)
Zymeworks Reports Quarterly Results, Raises 2026 Guidance
TipRanks (Mon, 9-Nov 5:21 PM ET)
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Globe Newswire (Mon, 9-Nov 4:05 PM ET)
Business Wire (Tue, 27-Oct 7:00 AM ET)
Globe Newswire (Sat, 24-Oct 2:30 AM ET)
Globe Newswire (Fri, 23-Oct 6:00 AM ET)
Globe Newswire (Mon, 19-Oct 6:00 AM ET)
Globe Newswire (Thu, 15-Oct 6:00 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of November 13, 2026, ZYME stock price declined to $26.24 with 733,034 million shares trading.
ZYME has a beta of -0.10, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.00 to the broad based SPY ETF.
ZYME has a market cap of $1.85 billion. This is considered a Small Cap stock.
Last quarter Zymeworks reported $256 million in Revenue and $2.28 earnings per share. This beat revenue expectation by $30 million and exceeded earnings estimates by $.05.
In the last 3 years, ZYME traded as high as $31.97 and as low as $7.42.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, DFAS.
ZYME has outperformed the market in the last year with a return of +41.8%, while the SPY ETF gained +13.4%. In the last 3 month period, ZYME beat the market returning +1.9%, while SPY returned -2.8%. However, in the most recent 2 weeks ZYME has underperformed the stock market by returning -8.3%, while SPY returned -0.2%.
ZYME support price is $25.54 and resistance is $27.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.